or Try an Advanced Search...

    Resistant Prostate Cancer Stocks List

    Symbol Grade Name % Change
    EXEL B Exelixis, Inc. 0.45
    CRDF D Cardiff Oncology, Inc. -0.20
    AMGN D Amgen Inc. 0.75
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes

    Related ETFs - A few ETFs which own one or more of the above listed Resistant Prostate Cancer stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 17.16
    BIS B ProShares UltraShort Nasdaq Biotechnology 8.87
    IBBQ D Invesco Nasdaq Biotechnology ETF 8.62
    PBE D PowerShares Dynamic Biotech & Genome 8.56
    IBB D iShares Nasdaq Biotechnology Index Fund 8.29
    View all Resistant Prostate Cancer ETFs...
    Compare ETFs
    Compare BIS to IBB Compare BIS to PBE Compare PBE to IBB

        Resistant Prostate Cancer Stocks Recent News

        Date Stock Title
        Nov 21 AMGN Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
        Nov 21 AMGN Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares
        Nov 21 AMGN Amgen picks prolific biotech founder Chang as new top scientist
        Nov 21 AMGN Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
        Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
        Nov 20 AMGN SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
        Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
        Nov 19 AMGN Amgen Stock Has High Implied Volatility. An Iron Condor Takes Advantage.
        Nov 19 AMGN Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 18 AMGN Amgen Sells Off: Keep Calm And Buy The Dip
        Nov 18 AMGN Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now?
        Nov 18 AMGN Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
        Nov 16 AMGN The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
        Nov 16 AMGN 2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
        Nov 16 AMGN The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period
        Nov 15 AMGN Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
        Nov 14 AMGN AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes
        Resistant Prostate Cancer

        Resistant prostate cancer is a type of prostate cancer that has become resistant to hormone therapy, which is the most common form of treatment for prostate cancer. This type of cancer is more difficult to treat and may require more aggressive treatments such as chemotherapy or radiation therapy.

        Browse All Tags